US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

Yutrepia is a dry powder formulation of treprostinil, a prostacyclin analog. It is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort. Yutrepia was was tentatively approved by the Food and Drug Administration last year (see our article here), but the agency was waiting for regulatory exclusivity of a competing product […]

US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease Read Post »

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025

The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025 Read Post »

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova

Alena’s journey transcends ordinary resilience. After battling pulmonary hypertension for a decade, surviving two double lung transplants, and undergoing over 200 photopheresis sessions, she now embraces life with just 34% lung function—yet lives it fully. Her story bridges cultures, identities, and the profound gift of donated organs. As she marks 11 years since her first

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova Read Post »

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025

Globally, over 4,500 lung transplants are performed annually. Pulmonary Arterial Hypertension represents a unique transplantation indication because: Given these specific challenges, the authors developed guidelines for managing Pulmonary Arterial Hypertension patients who are lung transplant candidates through a modified Delphi study. The expert panel reached unanimous consensus on several key aspects of lung transplantation for

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025 Read Post »

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025

Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept. Withdrawal of selexipag was found safe,

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025 Read Post »

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025

A systematic review and meta-analysis to determine whether tacrolimus or cyclosporine is more effective at reducing chronic lung allograft dysfunction (CLAD) in lung transplant patients was publshed on the British Medical Journal in April 2025. The researchers analyzed 4 randomized trials involving 662 patients with a mean age of 45-55 years, mostly with Chronic Obstructive

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025

A very important update on the phase 3 ZENITH trial for Winrevair (sotatercept) in pulmonary arterial hypertension was presented today at the American College of Cardiologists Annual Scientific Session in Boston, USA. The ZENITH trial evaluated Winrevair compared to placebo in adults with PAH, WHO Group 1, functional class III or IV, at high risk

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025 Read Post »

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025

Communication plays a crucial role in organ donation processes. According to the Association of Organ Procurement Organizations (AOPO), terminology choices can significantly impact public perception, potentially creating unnecessary fear that reduces donation rates. AOPO advocates for language that honors donors’ contributions and builds public confidence in the donation system. Recommended Terminology Shifts Surgical Procedure Terminology

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025

Link: Liquidia Corporation announced on March 28, 2025, that the US Food and Drug Administration has accepted its resubmitted new drug application for YUTREPIA (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA had previously granted tentative approval for both indications (see our

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT), is schedule to give a TedX talk about ”The power of three: death, life and the gift in between”. He has written on his LinkedIn page that he will recount three stories “that capture

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025 Read Post »

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025

This review, published on Expert Opinion on Pharmacotherapy on March 19, 2025, chronicles the evolution of pulmonary arterial hypertension (PAH) treatment from historical milestones to current challenges. Beginning with Ernst von Romberg’s first clinical description in 1891 and the advent of cardiac catheterization, pulmonary arterial hypertension diagnosis and treatment have advanced significantly in past decades.

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025 Read Post »

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025

Corsair Pharma, Inc. is a private biopharmaceutical company. The company has just announced the successful completion of a preclinical program for Its treprostinil Prodrug Transdermal System and its plans to start a Phase 1 trial in Q2 of 2025. The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025 Read Post »

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

TRANSLATE »
Scroll to Top